Lewis Silkin acquires tech and life sciences firm

Lewis Silkin has integrated MSK into its practice to better manage complex portfolios across various tech sectors.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Regulation & Industry

FDA targets faster generic approvals in drive to slash drug prices

27 August 2026 Dozens of new and revised guidances could make it faster and less costly to bring generics to market, as the US ramps up pressure on drug prices.

Biotech

China-origin biotech assets and the hidden question of IP ownership

27 August 2026 As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science—it’s about who controls the underlying IP, says Paul Calvo of Sterne Kessler

Careers

Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice

26 August 2026 The new practice head has represented life sciences clients in numerous high-profile disputes, and will be an “invaluable resource for our clients”, according to the firm.

More features

FDA targets faster generic approvals in drive to slash drug prices

China-origin biotech assets and the hidden question of IP ownership

Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice

The buyers' wishlist: What makes a life sciences deal stack up?

UK appoints ex-engineer as new intellectual property Minister

Stris & Maher opens new Dallas office with partner hires

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

10x Genomics dealt major blow in sequencing fight

Lewis Silkin acquires tech and life sciences firm

More on this story

Editor's picks

Editor's picks

More features